NEVVI Medicare utilization intelligence

← back

SHAH, KETANMD NPI 1083664023 Clinician

Hematology-Oncology · DAYTON, OH

Specialty Hematology-Oncology — from billed Medicare claims
Trained NEW YORK MEDICAL COLLEGE — medical school, self-reported to CMS
In practice about 35 years since medical school (class of 1991, self-reported to CMS)
Location DAYTON, OH · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 31 codes billed · 29,599 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
DAYTON PHYSICIANS LLC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2022-01

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J0897 Injection, denosumab, 1 mg
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96413 Administration of chemotherapy into vein, 1 hour or less
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96375 Injection of additional new drug or substance into vein
96372 Injection of drug or substance under skin or into muscle
A9595 Piflufolastat f-18, diagnostic, 1 millicurie
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
96415 Administration of chemotherapy into vein, each additional hour
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
99496 Transitional care management services for problem of high complexity
71260 Ct scan of chest with contrast
99195 Drawing of blood for a medical problem
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.